论文部分内容阅读
对７０例前列腺癌，８５例前列腺良性增生，２５例非典型性增生和２５例正常前列腺进行了ＡＢＨ血型抗原检测。正常组１９例（７６％）阳性，良性增生组（ＰＢＨ）５６例（６０．９％）阳性，两组比较Ｐ＞０．０５，非典型增生组（ＰＡＨ）１１例（４４％）阳性，前列腺癌（ＰＣ）９例（１２．９％）阳性。ＰＢＨ组与ＰＡＨ组阳性率比较Ｐ＜０．０５，ＰＣ组与ＰＡＨ组比较Ｐ＜０．０１．ＡＢＨ血型抗原阳性颗粒在三组病变的分布也不相同。提示血型物质可作为鉴别前列腺良恶性病变的标记物，非典型性增生为交界性病变。
ABH blood group antigen was detected in 70 cases of prostate cancer, 85 cases of benign prostatic hyperplasia, 25 cases of atypical hyperplasia and 25 cases of normal prostate. In the normal group, 19 cases (76%) were positive, while 56 cases (60.9%) were positive in the benign hyperplasia group (PBH), P> 0.05 in the two groups and 11 cases (44%) in the atypical hyperplasia group (PAH) Prostate cancer (PC) in 9 cases (12.9%) were positive. The positive rates of PBH group and PAH group were P <0.05, and those of PC group and PAH group were P <0.01. ABH blood group antigen-positive particles in the distribution of the three groups of lesions are not the same. Prompt blood group substances can be used as markers to identify benign and malignant prostatic lesions, atypical hyperplasia as borderline lesions.